title: Solifenacin objectively decreases urinary sensation in women with overactive bladder syndrome.
abstract: OBJECTIVE
  To evaluate the test-retest reliability of a device that measures urinary sensation during cystometry, and to use that device to determine whether treatment of overactive bladder syndrome (OAB) with solifenacin is associated with a change in urinary sensation.
  
  
  METHODS
  Overall 15 women were recruited for this study, ten women with OAB and urodynamically demonstrated detrusor overactivity and five controls without OAB underwent filling cystometry twice with contemporaneous, continuous recording of urinary sensation. Women with OAB received solifenacin 10 mg daily during the weeks between testing. We compared the areas under the initial and repeat sensation-volume curves.
  
  
  RESULTS
  While taking solifenacin, the maximum cystometric capacity increased from 329 ± 168 ml to 464 ± 123 ml (P < 0.002), and the area under the bladder volume-sensation curve decreased (P < 0.0001). Untreated controls did not exhibit these changes.
  
  
  CONCLUSIONS
  We present psychometric data demonstrating improved bladder sensation during the treatment of OAB with solifenacin. If clinical correlations are confirmed by future study, such urinary sensation measures may prove useful as assessment, treatment predictor, or outcome measures in OAB research and/or clinical care.
authors: Department of Obstetrics and Gynecology, Rambam Health Care Campus, Technion Faculty of Medicine, 6 Ha'Aliya Street, 31096 Haifa, Israel. LowensteinMD@gmail.com
authors: Lior
authors: L
authors: Lowenstein
authors: Kimberly
authors: K
authors: Kenton
authors: Elizabeth R
authors: ER
authors: Mueller
authors: Linda
authors: L
authors: Brubaker
authors: Edmond
authors: E
authors: Sabo
authors: Ramón A
authors: RA
authors: Durazo-Arivzu
authors: Mary P
authors: MP
authors: Fitzgerald
mesh_terms: D000368:Aged; D003950:Diagnostic Techniques, Urological / Q000295:instrumentation; D004867:Equipment Design; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D011237:Predictive Value of Tests; D011812:Quinuclidines / Q000008:administration & dosage / Q000627:therapeutic use*; D015203:Reproducibility of Results; D012677:Sensation / Q000187:drug effects*; D000069464:Solifenacin Succinate; D013577:Syndrome; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000294:innervation / Q000503:physiopathology*; D053201:Urinary Bladder, Overactive / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics
chemical_list: D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate